Henry Meds

About Henry Meds

Henry Meds has built a massive following in the compounded GLP-1 market, driven by strong patient satisfaction and a unique unlimited telehealth visits model that removes barriers to ongoing medical support. Founded in 2021 with roots in hormone therapy, the platform has expanded aggressively into GLP-1 weight loss.

The medication offerings include compounded semaglutide and compounded tirzepatide in both injectable and oral/sublingual formats — a delivery flexibility that many competitors lack. The oral/sublingual option is particularly appealing for patients who are needle-averse. Monthly pricing ranges from $249 to $399, placing Henry Meds in the mid-to-upper range for compounded medications.

Patient satisfaction metrics are outstanding: a 4.5 Trustpilot rating across 12,400+ reviews puts Henry Meds among the top-rated GLP-1 providers by review volume and quality. The unlimited telehealth visits model means patients can check in with providers as often as needed without additional consultation fees — a genuine value-add for patients who want more hands-on guidance.

The main concern is the F BBB rating, which creates a stark contrast with the excellent Trustpilot performance. This pattern — high patient satisfaction but poor BBB standing — often indicates rapid growth outpacing complaint-resolution infrastructure. It’s worth monitoring but may not reflect the typical patient experience.

Henry Meds operates as a compounded-only, self-pay platform with no insurance accepted. The clinical program is adequate (medium provider quality, medium support) but doesn’t include lab testing or dietitian access. For patients comfortable with the compounded model who value delivery format flexibility and unlimited provider access, Henry Meds delivers.

Henry Meds GLP-1 Medications

At a Glance